Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes

European Journal of Pharmacology

Volumn 578, Issue 2-3, 2008, Pages 142-147

  Benyamina, Amine ^a   Arbus, Christophe ^b   Nuss, Philippe ^c   Garay, Ricardo P ^d   Neliat, Gervais ^e   Hameg, Ahcène ^f  

^a HÔPITAL PAUL BROUSSE   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CEREP   (France)

^f SANOFI   (France)

Author keywords

Affinity; Cyamemazine; Guinea pig cerebellum; Radioligand binding; Rat cerebral receptors; Recombinant human receptor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BACLOFEN; BEMESETRON; CLOZAPINE; CYAMEMAZINE; CYAMEMAZINE SULFOXIDE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE RECEPTOR; KETANSERIN; MEPYRAMINE; METHOCTRAMINE; MONODESMETHYL CYAMEMAZINE; MUSCIMOL; NEUROTRANSMITTER RECEPTOR; PHENOTHIAZINE DERIVATIVE; PIRENZEPINE; PRAZOSIN; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CELL STRAIN HEK293; CEREBELLUM; CHO CELL; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; HUMAN; HUMAN CELL; INSOMNIA; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HUMANS; LIGANDS; METHYLATION; PHENOTHIAZINES; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE; RECEPTORS, HISTAMINE; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SULFOXIDES; TRANSFECTION;

EID: 37449020683     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.09.025     Document Type: Article

References (27)

1. Alvarez-Guerra M., d'Alche-Biree F., Wolf W.A., Vargas F., Dib M., and Garay R.P. 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity. Psychopharmacol. (Berl) 147 (2000) 412-417
2. Alvarez-Guerra M., Hameg A., Bayle F., Dib M., and Garay R.P. 5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle. Eur. J. Pharmacol. 454 (2002) 235-239
3. Bonhaus D.W., Bach C., De Souza A., Salazar F.H.R., Matsuoka B.D., Zuppan P., Chan H.W., and Eglen R.M. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol. 115 (1995) 622-628
4. Bourin M., Nic Dhonnchadha B.A., Claude Colombel M., Dib M., and Hascoet M. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behavioural Brain Res. 124 (2001) 87-95
5. Bourin M., Dailly E., and Hascoet M. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev. 10 (2004) 219-220
6. Bowery N.G., Hill D.R., and Hudson A.L. Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes. Br. J. Pharmacol. 78 (1983) 191-206
7. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
8. Dini S., Caselli G.F., Ferrari M.P., Giani R., and Clavenna G. Heterogeneity of [3H]-mepyramine binding sites in guinea pig cerebellum and lung. Agents Actions 33 (1991) 181-184
9. Dorje F., Wess J., Lambrecht G., Tacke R., Mutschler E., and Brann M.R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256 (1991) 727-733
10. Favre J.D., Allain H., Aubin H.J., Frija-Orvoen E., Gillet C., Lejoyeux M., Payen A., Weber M., Garcia-Acosta S., Kermadi I., and Dib M. Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome. Hum. Psychopharmacol. 20 (2005) 511-519
11. Grandy D.K., Marchionni M.A., Makam H., Stofko R.E., Alfano M., Frothingham L., Fischer J.B., Burke-Howie K.J., Bunzow J.R., Server A.C., and Civelli O. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc. Natl. Acad. Sci. (USA) 86 (1989) 9762-9766
12. Greengrass P., and Bremner R. Binding characteristics of [3H]-prazosin to rat brain alpha-adrenergic receptors. Eur. J. Pharmacol. 55 (1979) 323-326
13. Gury C., Fabre C., Hameg A., Simo E., Surugue J., Garay R.P., and Welcomme N. Prescription d'antipsychotiques en milieu hospitalier spécialisé. Inf. Psychiatr. 82 (2006) 503-509
14. Hameg A., Bayle F., Nuss P., Dupuis P., Garay R.P., and Dib M. Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem. Pharmacol. 65 (2003) 435-440
15. Hindmarch I., and Shamsi Z. Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin. Exp. Allergy 29 (1999) 133-142
16. Hode Y., Reimold M., Demazieres A., Reischl G., Bayle F., Nuss P., Hameg A., Dib M., and Macher J.P. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). Psychopharmacol. (Berl) 180 (2005) 377-384
17. Hope A.G., Peters J.A., Brown A.M., Lambert J.J., and Blackburn T.P. Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-As) subunit stably expressed in HEK 293 cells. Br. J. Pharmacol. 118 (1996) 1237-1245
18. Lemoine P., Kermadi I., Garcia-Acosta S., Garay R.P., and Dib M. Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Progress Neuro-Psychopharmacol. Biol. Psychiatry 30 (2006) 131-137
19. Monti J.M., and Jantos H. Effects of activation and blockade of 5-HT2A/2C receptors in the dorsal raphe nucleus on sleep and waking in the rat. Progress Neuro-Psychopharmacol. Biological Psychiatry 30 (2006) 1189-1195
20. Najam A.S., Colene D.D., Gary W.W., and Julie Y.C. Cloned human 5-HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation. J. Pharm. Pharmacol. 56 (2004) 1267-1274
21. Peinado J., Hameg A., Garay R.P., Bayle F., Nuss P., and Dib M. Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine. Naunyn Schmiedeberg's Arch. Pharmacol. 367 (2003) 134-139
22. Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J., and Capon D.J. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 6 (1987) 3923-3929
23. Shen Y., Monsma F.J., Metcalf M.A., Jose P.A., Hamblin M.W., and Sibley D.R. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J. Biol. Chem. 68 (1993) 18200-18204
24. Snodgrass S.R. Use of [3H]muscimol for GABA receptor studies. Nature 273 (1978) 392-394
25. Stam N.J., Vanderheyden P., van Alebeek C., Klomp J., de Boer T., van Delft A.M.L., and Olijve W. Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT2C receptor. European Journal of Pharmacology. Mol. Pharmacol. 269 (1994) 339-348
26. Uhlen S., and Wikberg J.E. Rat spinal chord alpha2-adrenoceptors are of the alpha2A-subtype : comparison with alpha2A and alpha2B-adrenoceptors in rat spleen, cerebral cortex and kidney using 3H-RX821002 ligand binding. Pharmacol. Toxicol. 69 (1991) 341-350
27. Van Tol H.H.M., Wu C.M., Guan H.G., Ohara K., Bunzow J.R., Civelli O., Kennedy J., Seeman P., Niznik H.B., and Jovanovic V. Multiple dopamine D4 receptor variants in the human population. Nature 358 (1992) 149-152